Loading organizations...
§ Private Profile · San Francisco, CA, USA
Developing selective PI3K inhibitors for cancer and inflammatory diseases.
Pathway Therapeutics has raised $12.0M across 2 funding rounds.
Pathway Therapeutics has raised $12.0M in total across 2 funding rounds.
Pathway Therapeutics has raised $12.0M across 2 funding rounds. Most recently, it raised $7.5M Other Equity in May 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 25, 2011 | $7.5M Venture Round | CM Capital, GBS Venture Partners | — | Announced |
| Aug 10, 2010 | $4.5M Series A Plus | CM Capital, GBS Venture Partners | Breast Cancer Research Trust, NEW Zealand Growth Capital Partners, Trans Tasman Commercialisation Fund | Announced |
Pathway Therapeutics has raised $12.0M in total across 2 funding rounds.
Pathway Therapeutics's investors include CM Capital, GBS Venture Partners, Breast Cancer Research Trust, New Zealand Growth Capital Partners, Trans Tasman Commercialisation Fund.